Clinical research company George Clinical said on Thursday that its health and medical expertise, operational infrastructure and data science teams are actively advising stakeholders on potential COVID-19 vaccine and treatment studies.

With deep roots in the Asia-Pacific (APAC) region and knowing geographic pattern of the COVID-19 pandemic, the company's team has adapted and applied learnings to trials in other locations as the pandemic spread brings uncommon challenges to ongoing clinical trials.

In this extraordinary situation, the company's is working with regulatory bodies and local ethics committees across the USA, UK, Europe and APAC to ensure and speed up the start up trial. The operations and data sciences teams bring expertise to provide unique solutions to new study challenges on COVID-19 solutions in order to expedite trial execution globally.

Through flexibility around the study design and operational implementation, the data can be generated quickly, with highest focus on patient safety and the treatments can be adequately reviewed for evaluation and approval in an expeditious manner, added the company.